Stearic acid nanoparticles successfully loaded LL-37 antimicrobial peptide without altering their shape, maintaining activity against Streptococcus pyogenes.
Preserved antibacterial activityLL-37 retained its ability to kill Streptococcus pyogenes even after encapsulation in lipid nanoparticles
What the researchers found
The researchers found that the type of organic solvent used during manufacturing had a major effect on nanoparticle shape. Chloroform produced the best spherical nanoparticles. Size and polydispersity were affected by surfactant concentration, stearic acid concentration, and homogenization amplitude.
Once optimized, the nanoparticles were successfully loaded with LL-37. The LL-37-loaded nanoparticles maintained their morphology and cytocompatibility (did not harm cells). They showed antibacterial activity against the reference strain of Streptococcus pyogenes (ATCC 12384).
Why it matters
LL-37 is the body's own antimicrobial peptide but breaks down quickly when used as a drug. Encapsulating it in lipid nanoparticles could protect it from degradation and deliver it to infection sites. Streptococcus pyogenes causes conditions ranging from strep throat to necrotizing fasciitis, and antibiotic-resistant strains are emerging.
The numbers in context
- Optimal solvent: chloroform for spherical morphology
- LL-37 loading did not alter morphology or cytocompatibility
- Active against Streptococcus pyogenes ATCC 12384
- Key parameters: surfactant concentration, stearic acid concentration, homogenization amplitude
How the study worked
Emulsification/solvent diffusion method was used to fabricate stearic acid nanoparticles. Manufacturing parameters (solvent type, surfactant concentration, stearic acid concentration, homogenization amplitude) were systematically optimized. LL-37 was loaded into optimized nanoparticles. Properties measured included morphology, size, polydispersity, cytotoxicity, and antibacterial activity.
Who was studied
In vitro formulation study testing LL-37-loaded nanoparticles against Streptococcus pyogenes
What this study cannot tell us
Antibacterial activity was tested against only one bacterial strain. No in vivo testing was performed. The use of chloroform as a manufacturing solvent raises questions about residual solvent safety. The study focused on manufacturing optimization rather than therapeutic efficacy. No release kinetics data was reported.
How to read the evidence
Rated preliminary: proof-of-concept nanoparticle formulation study tested against a single bacterial strain in vitro.
When this study was published
Published in 2024. Lipid nanoparticle technology gained momentum from COVID-19 mRNA vaccine success.
The bigger picture
LL-37 is the body's own antimicrobial peptide but breaks down quickly when used as a drug. Encapsulating it in nanoparticles could protect it from degradation and deliver it to infection sites — relevant for wound infections and antibiotic-resistant bacteria.
Questions still open
- Will LL-37 nanoparticles work against antibiotic-resistant strains?
- Can these nanoparticles be incorporated into wound dressings?
Common questions
What is LL-37?
Why put LL-37 in nanoparticles?
Read the original research
Stearic acid-based nanoparticles loaded with antibacterial peptides - Bacitracin and LL-37: Selection of manufacturing parameters, cytocompatibility, and antibacterial efficacy.
International journal of pharmaceutics, 667(Pt A), 124876
Citation
Reczyńska-Kolman, Katarzyna; Ochońska, Dorota; Brzychczy-Włoch, Monika; Pamuła, Elżbieta. (2024). Stearic acid-based nanoparticles loaded with antibacterial peptides - Bacitracin and LL-37: Selection of manufacturing parameters, cytocompatibility, and antibacterial efficacy.. International journal of pharmaceutics, 667(Pt A), 124876. https://doi.org/10.1016/j.ijpharm.2024.124876